


## STATUS OF THE CLAIMS

1. (currently amended) A composition comprising a drug-eluting stent media; wherein said drug-eluting stent media comprises a pharmaceutical composition designed to bind a mitochondrial oligomycin sensitivity conferring protein component in a mammalian subject; wherein said pharmaceutical composition comprises an agent capable of binding a mitochondrial oligomycin sensitivity conferring protein component, wherein said agent does not bind to a central benzodiazepine receptor and binds only with low affinity to a peripheral benzodiazepine receptor, wherein said agent is:



- 2-11. (canceled).
12. (currently amended) The composition of Claim 1, wherein said drug-eluting stent media is coated on ~~in contact with~~ a drug-eluting stent.
13. (previously presented) The composition of Claim 12, wherein said drug-eluting stent is seeded with endothelial cells.
14. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anticoagulant drug.
15. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antiplatelet drug.

16. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an antimicrobial agent.
17. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-inflammatory agent.
18. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises an anti-metabolic agent.
19. (previously presented) The composition of Claim 1, wherein said drug-eluting stent media further comprises a vasoreactive agent.
20. (previously presented) The composition of Claim 14, wherein said vasoreactive agent is a nitric oxide releasing agent.
21. (new) The composition of Claim 1, wherein said subject is a human being.